The Hetero Ring Has 8 Or More Ring Carbons Patents (Class 514/28)
-
Patent number: 6281197Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1&agr;, IL-1&bgr; and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: December 17, 1999Date of Patent: August 28, 2001Assignee: Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Publication number: 20010014336Abstract: A stable injectable composition includes a non-aqueous parasitic agent in a therapeutically effect amount, chosen from the group of avermectin, ivermectin, doramectin, abamectin, milbemycin and moxidecting, and an antigen in combination with a liquid carrier that also acts as an adjuvant for use with warm blooded animals and a method for treating parasitic diseases and preventing bacterial and viral diseases in warm blooded animals.Type: ApplicationFiled: February 21, 2001Publication date: August 16, 2001Applicant: Ashmont Holdings LimitedInventor: Colin Manson Harvey
-
Publication number: 20010003589Abstract: Pharmaceutical compositions for oral administration comprising a cyclosporin or macrolide as active ingredient, and a polyethoxylated saturated hydroxy-fatty acid.Type: ApplicationFiled: December 15, 2000Publication date: June 14, 2001Inventors: Klaus Neuer, Monika Petszulat, Hatto Walch
-
Patent number: 6174864Abstract: A preventive and curative agent for inflammatory bowel diseases is disclosed which has as an active ingredient thereof a chromanol glucoside represented by the following general formula (1) (wherein R1, R2, R3, and R4 represent identically or differently either a hydrogen atom or a lower alkyl group, R5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, X represents a monosaccharide residue or an oligosaccharide residue having the hydrogen atom in the hydroxyl group thereof optionally substituted with a lower alkyl group or a lower acyl group, n represents an integer of 0-6, and m represents an integer of 1-6). Owing to the use, as an active ingredient, of the chromanol glucoside excelling in water solubility and possessing an oxidization resisting action and a free radical resisting action, the agent can conspicuously repress the lesion of an inflammatory bowel disease and prominently ameriolate the condition of disease.Type: GrantFiled: August 9, 1999Date of Patent: January 16, 2001Assignee: CCI CorporationInventors: Toshikazu Yoshikawa, Norimasa Yoshida, Hironobu Murase
-
Patent number: 6165985Abstract: Ring-contracted N-demethyl-N-isopropyl-erythromycin-A derivatives having a modified side chain and gastrointestinally effective motilin-agonistic properties and the preparation thereof are described.Type: GrantFiled: June 23, 1999Date of Patent: December 26, 2000Assignee: Solvay Pharmaceuticals GmbHInventors: Daniel Jasserand, Ulf Preuschoff, Christian Eeckhout
-
Patent number: 6159463Abstract: Purified DNA encoding LCF and the recombinant proteins expressed from such DNA are disclosed. In addition, the invention provides methods for suppressing an LCF-CD4 interaction and screening candidate LCF agonists or antagonists. The invention also provides compositions and methods useful for stimulating proliferation of CD4+ T-cells in a mammal.Type: GrantFiled: December 29, 1995Date of Patent: December 12, 2000Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 6121243Abstract: A method for treatment of prophylaxis of skin against ageing, against inflammation and for protection from photoreaction and oxidative influences which comprise applying a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives to the skin.Type: GrantFiled: September 8, 1997Date of Patent: September 19, 2000Assignee: Beiersdorf AGInventors: Ghita Lanzendorfer, Franz Stab, Sven Untiedt
-
Patent number: 6107283Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: May 28, 1999Date of Patent: August 22, 2000Assignee: Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Patent number: 6083921Abstract: The present invention provides a pharmaceutical composition comprising an extract or combination of extracts having an antiviral, antibacterial, or immunomodulating property, wherein the extract or combination of extracts is obtained from a combination of plants wherein at least one plant is selected from each of the genuses Labiatae, Caprifoliaceae, and Oleaceae. A preferred extract is obtained from Radix scutellaria, Flos lonicera, and Fructus forsythiae. The present invention further provides a pharmaceutical composition comprising baicalin, chlorogenic acid and forsythiaside in isolated and purified form. The present invention further provides certain novel derivatives of baicalin, chlorogenic acid and forsythiaside. The present invention additionally provides processes for preparing the extracts as well as baicalin, chlorogenic acid, and forsythiaside in isolated and purified forms.Type: GrantFiled: January 12, 1998Date of Patent: July 4, 2000Inventor: Kai Jian Xu
-
Patent number: 6083706Abstract: Methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a compound that inhibits the binding of the leaderless protein and a transport molecule are provided. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta., CNTF and HIV-tat. These methods are useful in treatment of various conditions, including tumors and diabetes.Type: GrantFiled: February 25, 1998Date of Patent: July 4, 2000Assignee: Ciblex CorporationInventors: Robert Z. Florkiewicz, Andrew Baird
-
Patent number: 6071885Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: December 14, 1998Date of Patent: June 6, 2000Assignee: Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Patent number: 6022866Abstract: A method is provided of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of endothelial cells into the area of trauma.Type: GrantFiled: March 24, 1995Date of Patent: February 8, 2000Assignee: Hyal Pharmaceutical CorporationInventors: Rudolf Edgar Falk, Samuel Simon Asculai, Eva Anne Turley
-
Patent number: 5989566Abstract: The invention relates to certain stable vaccine compositions comprising a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof; at least one antigen; a dispersing agent; an adjuvant; a water soluble organic solvent; and saline or water or mixtures thereof. The invention further relates to stable compositions as described above of a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof, but without an antigen. The invention also relates to a method for preventing or controlling helminthiasis, infection by acarids and arthropod endo-and ectoparasites and bacterial and viral disease in warm-blooded animals by the parenteral administration of compositions of the invention. The invention further relates to a process for the preparation of the invention compositions.Type: GrantFiled: June 28, 1996Date of Patent: November 23, 1999Assignee: American Cyanamid CompanyInventors: Ramune Marija Cobb, Christopher Leigh Schwartzkoff
-
Patent number: 5981500Abstract: A 5-oximino-25-substituted avermectin B1 or B2 monosaccharide of formula I herein has use in the treatment of parasitic infections in animals and humans. The compounds may be prepared from corresponding 5-keto substituted derivatives.Type: GrantFiled: May 9, 1997Date of Patent: November 9, 1999Assignee: Pfizer Inc.Inventors: Bernard Frank Bishop, Michael Stephen Pacey, David Austen Perry
-
Patent number: 5965718Abstract: Sarcodictyin A and B, eleutherobin, and bioactive analogs thereof synthesized using solid phase and solution phase chemistries. The synthetic method employs an attachment of common precursors, e.g., compounds 1880 or 200, on a solid support for generating conjugates 230 and 240, followed by standard chemical manipulations. A combinatorial library of sarcodictyins and eletherobin analogs was constructed with modified C-8 ester, C-15 ester and C-4 ketal functionalities and was screened for activity with respect to tubulin polymerization and cytotoxic activity against tumor cells, including Taxol-resistant lines. Compounds 600, 610, 630, 660-700, 730, 760, 850, and 920 were identified to be of equal or superior biological activities as compared to their corresponding natural product.Type: GrantFiled: September 1, 1998Date of Patent: October 12, 1999Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, Floris VanDelft, Seijiro Hosokawa, Sanghee Kim, Tianhu Li, Takashi Ohshima, Jeff Pfefferkorn, Dionisios Vourloumis, Jin-You Xu, Nicolas Winssinger
-
Patent number: 5912235Abstract: Ring-contracted N-demethyl-N-isopropyl-erythromycin-A-spiroacetal compounds corresponding to formula I ##STR1## having gastrointestinally effective motilin-agonistic properties and the preparation thereof.Type: GrantFiled: October 21, 1997Date of Patent: June 15, 1999Assignee: Solvay Pharmaceuticals GmbHInventors: Dagmar Hoeltje, Ulf Preuschoff, Christian Eeckhout, Emil Finner
-
Patent number: 5891855Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL,-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: February 12, 1996Date of Patent: April 6, 1999Assignee: The Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Patent number: 5840861Abstract: New A83543 components, including fermentation products A83543K, A835430, A83543P, A83543U, A83543V, A83543W and A83543Y and N-demethyl derivatives, and salts thereof, are useful for the control of insects and mites. The pseudoaglycones of the new A83543 components are useful for the preparation of A83543 components. Methods are provided for making the new A83543 components by culturing of Saccharopolyspora spinosa NRRL 18395, NRRL 18537, NRRL 18538, or NRRL 18539, or NRRL 18743 or NRRL 18719 or NRRL 18823 in suitable culture medium. Insecticidal and ectoparasiticidal compositions containing new A83543 components are also provided.Type: GrantFiled: February 8, 1995Date of Patent: November 24, 1998Assignee: DowElancoInventors: Jon S. Mynderse, Mary C. Broughton, Walter M. Nakatsukasa, James A. Mabe, Jan R. Turner, Lawrence Creemer, Mary L. B. Huber, Herbert A. Kirst, James W. Martin
-
Patent number: 5795871Abstract: 14- or 15-membered-ring macrolide compounds such as clarithromycin, erythromycin B, etc. have a potent antitumor effect on non-small cell lung cancers which are considered the most difficult tumors to be be subjected to surgical operation and chemotherapy, and are useful as a practical therapeutic agent of non-small cell lung cancer.Type: GrantFiled: October 23, 1996Date of Patent: August 18, 1998Assignee: Nobuhiro NaritaInventors: Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Eiji Kita
-
Patent number: 5776925Abstract: Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein -nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.Type: GrantFiled: January 25, 1996Date of Patent: July 7, 1998Assignee: Pharmacyclics, Inc.Inventors: Stuart W. Young, Richard A. Miller
-
Patent number: 5767096Abstract: Antimicrobial compounds having the formula ##STR1## wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen and C.sub.1 -to-C.sub.4 alkanoyl;R.sup.3 and R.sup.4 are selected from the group consisting of(a) R.sup.3 is hydrogen and R.sup.4 is hydroxy,(b) R.sup.3 is hydroxy and R.sup.4 is hydrogen,(c) R.sup.3 and R.sup.4 taken together are .dbd.O; or selected from the group consisting of hydrogen and hydroxy; andR.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, bromine and chlorine, with the proviso that at least one of R.sup.5 and R.sup.6 must be bromine. Also disclosed are pharmaceutical compositions comprising such compounds, methods of treating bacterial infection by the administration thereof and a process for preparing said compounds.Type: GrantFiled: July 12, 1996Date of Patent: June 16, 1998Assignee: Abbott LaboratoriesInventors: Jill E. Hochlowski, Marianna Jackson, James B. McAlpine, Ronald R. Rasmussen
-
Patent number: 5747465Abstract: This invention relates to the saccharide derivatives of macrocyclic compounds useful for the treatment of resistance to transplantion, autoimmune disease and fungal diseases.Type: GrantFiled: August 8, 1994Date of Patent: May 5, 1998Assignee: Pfizer Inc.Inventor: Kevin Koch
-
Patent number: 5733887Abstract: Antiparasitic compounds of the formula (I) ##STR1## where the broken lines between the 3-4 and 4-5 positions represent optional bonds and either (i) the 3-4 optional bond is present; the 4-5 optional bond is absent, R.sup.7 is absent and R.sup.6 is halogen atom, an isothiocyanate group, a diazo group, a thioureido group of formula NHCSNR.sup.15 R.sup.16 where R.sup.15 and R.sup.16 are independently H, C.sub.1 -C.sub.8 alkyl, cycloalkyl, aryl or aralkyl groups, an azido group or a C.sub.1 -C.sub.8 alkylcarbonyl-thio group, or (ii) the 4-5 optional bond is present, the 3-4 optional bond is absent, R.sup.6 is absent and R.sup.7 is a mercapto, C.sub.1 -C.sub.8 alkylthio, oxo, optionally substituted oximino or C.sub.1 -C.sub.8 alkylcarbonylthio group; or R.sup.7 is absent and R.sup.6 is CN, with the provisos that the compounds where R.sup.6 is .alpha.-fluoro and R.sup.2 is CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2 H.sub.5, C(CH.sub.3).dbd.CHCH.sub.3, C(CH.sub.3).dbd.CHC.sub.2 H.sub.5 and C(CH.sub.3).dbd.CHCH(CH.sub.Type: GrantFiled: November 20, 1995Date of Patent: March 31, 1998Assignee: Pfizer Inc.Inventor: Nigel Derek Walshe
-
Patent number: 5712253Abstract: Novel macrocyclic 13-membered ring-contracted compounds derived from erythromycins A and B having the Formula (I) ##STR1## and pharmaceutically acceptable salts thereof, wherein R, R.sup.1, R.sup.2, R.sup.3 and X are specifically defined, having use in treating gastrointestinal disorders associated with hypermotilinemia, pharmaceutical compositions thereof, a method of treating gastrointestinal disorders associated with hypermotilinemia with said pharmaceutical compositions, and processes for the preparation thereof.Type: GrantFiled: June 18, 1996Date of Patent: January 27, 1998Assignee: Abbott LaboratoriesInventors: Paul A. Lartey, Cynthia Burnell Curty, Ramin Faghih, Hugh Nerby Nellans, Albert Christian Petersen
-
Patent number: 5677332Abstract: This invention is directed to novel antiparasitic compounds of formula (I), wherein the broken line represents an optional bond, R.sup.1 and R.sup.4 being absent when this bond is present, R.sup.1, R.sup.3, R.sup.4 are independently H, OH, halo mercapto, oxo, oximino, or an organic radical, R.sup.2 and R.sup.7 are organic radicals, R.sup.6 is H or an organic radical and R.sup.12 is OH, halo, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.9 alkanoyloxy, or oximino optionally O-substituted by a C.sub.1 -C.sub.8 alkyl, alkenyl, alkynyl, aryl, trialkylsilyl, aralkyl or C.sub.1 -C.sub.9 alkanoyl group.Type: GrantFiled: December 22, 1995Date of Patent: October 14, 1997Assignee: Pfizer Inc.Inventor: Bernard Joseph Banks
-
Patent number: 5670364Abstract: New A83543 components, including fermentation products A83543K, A835430, A83543P, A83543U, A83543V, A83543W and A83543Y and N-demethyl derivatives, and salts thereof, are useful for the control of insects and mites. The pseudoaglycones of the new A83543 components are useful for the preparation of A83543 components. Methods are provided for making the new A83543 components by culturing of Saccharopolyspora spinosa NRRL 18395, NRRL 18537, NRRL 18538, or NRRL 18539, or NRRL 18743 or NRRL 18719 or NRRL 18823 in suitable culture medium. Insecticidal and ectoparasiticidal compositions containing new A83543 components are also provided.Type: GrantFiled: June 7, 1995Date of Patent: September 23, 1997Assignee: DowElancoInventors: Jon S. Mynderse, James A. Mabe, Jan R. Turner, Mary L. B. Huber, Mary C. Broughton, Walter M. Nakatsukasa, Lawrence Creemer, Herbert A. Kirst, James W. Martin
-
Patent number: 5670486Abstract: New A83543 components, including fermentation products A83543K, A83543O, A83543P, A83543U, A83543V, A83543W and A83543Y and N-demethyl derivatives, and salts thereof, are useful for the control of insects and mites. The pseudoaglycones of the new A83543 components are useful for the preparation of A83543 components. Methods are provided for making the new A83543 components by culturing of Saccharopolyspora spinosa NRRL 18395, NRRL 18537, NRRL 18538, or NRRL 18539, or NRRL 18743 or NRRL 18719 or NRRL 18823 in suitable culture medium. Insecticidal and ectoparasiticidal compositions containing new A83543 components are also provided.Type: GrantFiled: June 7, 1995Date of Patent: September 23, 1997Assignee: DowElancoInventors: Jon S. Mynderse, James A. Mabe, Jan R. Turner, Mary L. B. Huber, Mary C. Broughton, Walter M. Nakatsukasa, Lawrence Creemer, Herbert A. Kirst, James W. Martin
-
Patent number: 5637616Abstract: A method for the topical or systemic treatment of disorders mediated by proteases which result in skin or mucosal lesions, and in particular, pemphigus, cicatricial pemphigoid, bullous pemphigoid, lichen planus, and canker sores, is disclosed wherein the host is treated with an effective amount of N-acetyl ysteine or a derivative thereof, or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable diluent or carrier for systemic or topical delivery.Type: GrantFiled: October 5, 1993Date of Patent: June 10, 1997Assignee: Arcturus Pharmaceutical CorporationInventors: Richard J. Sharpe, Maureen H. McAloon, Stephen J. Galli, Kenneth A. Arndt
-
Patent number: 5626883Abstract: A vitamin C supplement comprising ascorbic acid, ascorbyl palmitate, niacinamide ascorbate, calcium ascorbate, magnesium ascorbate, potassium ascorbate, and sodium ascorbate which together can be administered to a human to avoid the transitory initial suppression of human NK cell activity which is present when ascorbic acid alone is administered. Also included is xylitol, lysine acetate, tetrasodium pyrophosphate, ribose, cysteine, and hesperidin which further prolongs the biological activity of ascorbic acid and promotes the uptake of ascorbic acid by human tissue.Type: GrantFiled: April 15, 1994Date of Patent: May 6, 1997Assignee: Metagenics, Inc.Inventor: Stephen M. Paul
-
Patent number: 5587371Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 24, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5559098Abstract: A stable topical formulation with good active ingredient release characteristics, comprising at least one macrolide antibiotic which is lipophilized with at least one former of oppositely charged ions which is selected from the group consisting of alkyl sulfates, alkylsulfonates, and alkyl salicylates, RX, where R represents a linear and/or branched alkyl group with 6-32 C atoms, and X represents a sulfate, sulfonate, or salicylate group.Type: GrantFiled: January 30, 1995Date of Patent: September 24, 1996Assignee: Roehm Pharma GmbHInventors: Wolfgang A. Wohlrab, Reinhard Neubert, Sybille Matschiner, Katrin Wellner
-
Patent number: 5508268Abstract: Stable parenteral antitumor formulations contain elsamitrucin salt, a stabilizer and a buffer. The formations are optionally stored in sealed containers under air or nitrogen headspace.Type: GrantFiled: August 12, 1993Date of Patent: April 16, 1996Assignee: Bristol-Myers SquibbInventors: Munir N. Nassar, Michael J. Reff, Sheeram N. Agharkar
-
Patent number: 5489576Abstract: A therapeutic agent for hemorrhoidal diseases, comprising, as an active ingredient, a diester phosphate compound of the formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each is a hydrogen atom or a methyl, or a pharmacologically acceptable salt thereof, and a method for treating hemorrhoidal diseases, comprising administering a pharmaceutically effective amount of said diester phosphate compound or a pharmacologically acceptable salt thereof.Type: GrantFiled: December 20, 1994Date of Patent: February 6, 1996Assignees: Senju Pharmaceutical Co., Ltd., Amato Pharmaceutical Products, Ltd.Inventors: Kenichi Yoshida, Etsunosuke Noda
-
Patent number: 5476843Abstract: A stable topical formulation with good active ingredient release characteristics, comprising at least one macrolide antibiotic which is lipophilized with at least one former of oppositely charged ions which is selected from the group consisting of alkyl sulfates, alkylsulfonates, and alkyl salicylates, RX, where R represents a linear and/or branched alkyl group with 6-32 C atoms, and X represents a sulfate, sulfonate, or salicylate group.Type: GrantFiled: October 4, 1993Date of Patent: December 19, 1995Assignee: Roehm Pharma GmbHInventors: Wolfgang A. Wohlrab, Reinhard Neubert, Sabine Matschiner, Katrin Wellner
-
Patent number: 5451581Abstract: This invention relates to the antibiotics LL-14E605.beta. and O-methyl-LL-14E605.beta. derived from the microorganism Sebekia benihana which are useful as antibacterial agents.Type: GrantFiled: May 21, 1993Date of Patent: September 19, 1995Inventors: May D. Lee, Peter T. Northcote, Mary Lechevalier
-
Patent number: 5418224Abstract: Ring-contracted N-demethyl-N-isopropylerythromycin A derivatives with gastrointestinally effective motilin-agonistic properties, a method for preparing such compounds, and pharmaceutical compositions containing them.Type: GrantFiled: December 23, 1992Date of Patent: May 23, 1995Assignee: Kali-Chemie Pharma GmbHInventors: Dagmar Hoeltje, Ulf Preuschoff, Christian Eeckhout
-
Patent number: 5350742Abstract: Avermectin derivatives are disclosed which incorporate two fluorine atoms at the 4' monosaccharide position, the 4" disaccharide position or the 23 position. Avermectin aglycone derivatives are also disclosed which incorporate two fluorine atoms at position 13 or 23. These difluoro avermectin analogs are derived from corresponding ketones and enones which in turn are prepared by chemical modification of naturally occurring avermectins. These compounds are used as antiparisitic, insecticidal and antihelmintic agents in humans and animals and compositions containing such compounds as the active ingredient thereof are also disclosed.Type: GrantFiled: June 10, 1993Date of Patent: September 27, 1994Assignee: Merck & Co., Inc.Inventors: Peter T. Meinke, Helmut Mrozik, Michael H. Fisher
-
Patent number: 5143906Abstract: Kedarcidin chromophore, a non-protein chromophore isolated from kedarcidin antitumor antibiotic, is obtained from purified or partially purified kedarcidin by solvent extraction and chromatographic procedures. The chromophore is characterized and found to contain substantially all of the antitumor activity of kedarcidin.Type: GrantFiled: September 26, 1991Date of Patent: September 1, 1992Assignee: Bristol-Myers Squibb CompanyInventor: John E. Leet
-
Patent number: 5061695Abstract: An antitumor substance BE-12406 or a pharmaceutically acceptable salt thereof, which is represented by the general formula ##STR1## and a method of producing the novel substance.Type: GrantFiled: January 30, 1990Date of Patent: October 29, 1991Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Hiroyuki Suda, Katuhisa Kojiri, Akira Okura, Koutaro Funaishi, Kenji Kawamura, Masanori Okanishi
-
Patent number: 4937232Abstract: Compositions for inhibiting protein kinase C, comprising an inhibitory amount of a compound having the formula: ##STR1## wherein Q is a hydrophobic group; wherein X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, which may be substituted by one or more halogens or C.sub.1 -C.sub.3 alkyl groups,wherein Y is ##STR2## wherein W is a halogen; wherein R.sub.1 and R.sub.2 may be the same or different and are selected from hydrogen, lower alkyl groups having from 1 to 7 carbon atoms, aralkyl, and aryl groups, andwherein Z is a phosphate or an organic group, and a pharmaceutically acceptable carrier material; and a method for inhibiting protein kinase C using such compositions.Type: GrantFiled: May 17, 1988Date of Patent: June 26, 1990Assignee: Duke UniversityInventors: Robert M. Bell, Carson Loomis, Yusuf Hannun
-
Patent number: 4920102Abstract: Novel ring-contracted macrolides which enhance gastrointestinal motility and novel methods and compositions for treating gtastrointestinal disorders in animals with these macrolides and with certain other previously known ring-contracted macrolides are provided.Type: GrantFiled: April 18, 1988Date of Patent: April 24, 1990Assignee: Eli Lilly and CompanyInventors: Jaswant S. Gidda, Herbert A. Kirst, David W. Robertson
-
Patent number: 4816450Abstract: Compositions for inhibiting protein kinase C, comprising an inhibitory amount of a compound having the formula: ##STR1## wherein Q is a hydrophobic group; wherein X is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, which may be substituted by one or more halogens or C.sub.1 -C.sub.3 alkyl groups,wherein Y is ##STR2## wherein W is a halogen; wherein R.sub.1 and R.sub.2 may be the same or different and are selected from hydrogen, lower alkyl groups having from 1 to 7 carbon atoms, aralkyl, and aryl groups, andwherein Z is a phosphate or an organic group, and a pharmaceutically acceptable carrier material; and a method for inhibiting protein kinase C using such compositions.Type: GrantFiled: September 15, 1986Date of Patent: March 28, 1989Assignee: Duke UniversityInventors: Robert M. Bell, Carson Loomis, Yusuf Hannun
-
Patent number: 4749694Abstract: Novel lysine esters used as absorption enhancing agents for gastrointestinally and rectally administered drugs. Also provided are processes for preparation of said lysine ester compounds as well as pharmaceutical formulations and methods for their use as absorption enhancing agents.Type: GrantFiled: April 26, 1984Date of Patent: June 7, 1988Assignee: Merck & Co., Inc.Inventors: Joseph A. Fix, Stefano A. Pogany
-
Patent number: 4707469Abstract: A ganglioside mixture, comprised of the gangliosides GM.sub.1, GD.sub.1a, GD.sub.1b and GT.sub.1b, has been found to possess significant analgesic or pain relieving activity. The mixture is, therefore, useful for treating pain due to various peripheral neuropathies and the mixture is more effective than the individual gangliosides which comprise the mixture.Type: GrantFiled: June 13, 1985Date of Patent: November 17, 1987Assignee: Fidia, S.p.A.Inventors: Francesco della Valle, Aurelio Romeo, Silvana Lorenzi
-
Patent number: 4613591Abstract: Adminiculum increasing the antitumor activities of mitomycin C and doxorubicin hydrochloride and decreasing the side effects associated with their use comprising an aqueous or aqueous organic solvent extract of a crude preparation of Astragali radix, Cinnamomi cortex, Rehmanniae radix, Paeoniae radix, Cnidii rhizoma, Atractylodis lanceae rhizoma, Angelicae radix, Ginseng radix, Hoelen and Glycyrrhizae radix, a method for preparing said adminiculum and a method for its use. In addition, compositions and methods for treating tumor-bearing patients are disclosed.Type: GrantFiled: June 29, 1983Date of Patent: September 23, 1986Assignee: Tsumura Juntendo Inc.Inventors: Masaki Aburada, Shigefumi Takeda, Eiko Itoh, Moe Matsushita, Eikichi Hosoya
-
Patent number: 4607024Abstract: A new salt of the macrolide antibiotic Josamycin with (-)-cis-1,4-epoxypropionylphosphonic acid, of formula (I) ##STR1## The salt (I), prepared from Josamycin base and phosphomycin, possesses favorable antimicrobial and pharmacokinetics properties.Type: GrantFiled: October 9, 1984Date of Patent: August 19, 1986Assignee: Schering S.p.A.Inventor: Alberto Bertelli
-
Patent number: 4558008Abstract: The novel glycopeptide antibiotic A-51568B is produced by submerged, aerobic fermentation of Nocardia orientalis NRRL 15232. A-51568B demonstrates antibiotic activity against gram-positive bacteria.Type: GrantFiled: December 13, 1983Date of Patent: December 10, 1985Assignee: Eli Lilly and CompanyInventors: LaVerne D. Boeck, Gary G. Marconi, Marvin M. Hoehn
-
Patent number: H1168Abstract: An agent and treatment for a subject susceptible to septic shock. The subject is treated with a PKC inhibitor, preferably wit a PKC inhibitor selected from the group consisting of lipid analogues. Preferred among the lipid analogues are sphingosine and its analogues. The inhibitors of this invention are administered, preferably by infusion in a suitable pharmaceutical carrier, in a range of 0.1 to 50 mg/Kg body weight preferably in the range of 0.5 to 25 mg/Kg body weight and most preferably in the range of 1 to 5 mg/Kg body weight.Type: GrantFiled: August 21, 1991Date of Patent: April 6, 1993Assignee: The United States of America as represented by the Secretary of the NavyInventors: Thomas M. McKenna, Taffy J. Williams